Revenue of Supernus Pharmaceuticals, Inc.
Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.
In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
|Company||Industry||Return on equity|
|PX Praxair, Inc.||NYSE > Basic Industries > Major Chemicals||27.08%|
|MXIM Maxim Integrated Products, Inc.||NASDAQ > Technology > Semiconductors||27.17%|
|TPIC TPI Composites, Inc.||NASDAQ > Energy > Industrial Machinery/Components||27.18%|
|TSEM Tower Semiconductor Ltd.||NASDAQ > Technology > Semiconductors||27.19%|
|NMRK Newmark Group, Inc.||NASDAQ||27.19%|
|TEP Tallgrass Energy Partners, LP||NYSE > Public Utilities > Natural Gas Distribution||27.22%|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||27.27%|
|OPNT Opiant Pharmaceuticals, Inc.||NASDAQ > Basic Industries > Precious Metals||2,031.11%|
|PBT Permian Basin Royalty Trust||NYSE > Energy > Oil & Gas Production||4,888.60%|
|IDXX IDEXX Laboratories, Inc.||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||8,410.92%|
|NRT North European Oil Royality Trust||NYSE > Energy > Oil & Gas Production||8,437.44%|
|CQH Cheniere Energy Partners LP Holdings, LLC||NYSEMKT > Public Utilities > Oil/Gas Transmission||9,523.81%|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||9,929.09%|